ArticleCancer2019
The role of cancer in marijuana and prescription opioid use in the United States: A population-based analysis from 2005 to 2014.
Article in Cancer, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed, 2 syntheses or guidelines pooled it, 46 citations in OpenAlex.
- Cannabis use among cancer survivors: a systematic review and meta-analysis.Archives of public health = Archives belges de sante publique · 2026Pooled it
- A Mapping Literature Review of Medical Cannabis Clinical Outcomes and Quality of Evidence in Approved Conditions in the USA from 2016 to 2019.Medical cannabis and cannabinoids · 2021Pooled it
- Cannabis use and perceptions among rural and urban cancer patients and survivors from a Pennsylvania cancer center.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2026Article
- Post-diagnosis cannabis use and its association with health status and quality of life in cancer survivors.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2026Article
- Cannabis stigma and symptom management considerations in cancer survivors: a mixed-methods exploration of patient perspectives.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2026Observational
- Cannabis Stigma and Symptom Management Considerations in Cancer Survivors: A Mixed-Methods Exploration of Patient Perspectives.Research square · 2025Article
- Characteristics of Cannabis Use Among Head and Neck Cancer Survivors.Laryngoscope investigative otolaryngology · 2025Article
- Prevalence and determinants of cigarette-cannabis co-use among US cancer survivors.Journal of cancer survivorship : research and practice · 2025Article
- A Multicenter Feasibility Study of a Novel Curriculum for Oncology Trainees Regarding Medical Cannabis.Journal of the National Comprehensive Cancer Network : JNCCN · 2025Article
- Perceptions, prevalence, and patterns of cannabis use among cancer patients treated at 12 NCI-Designated Cancer Centers.Journal of the National Cancer Institute. Monographs · 2024Article
- Patient out-of-pocket costs for cannabis use during cancer treatment.Journal of the National Cancer Institute. Monographs · 2024Article
- Patient-provider communication about the use of medical cannabis for cancer symptoms: a cross-sectional study.Journal of the National Cancer Institute. Monographs · 2024Article
- Cannabis use and patient-reported outcomes among patients at a comprehensive cancer center.Journal of the National Cancer Institute. Monographs · 2024Article
- The association of perceived cannabis risks and benefits with cannabis use since cancer diagnosis.Journal of the National Cancer Institute. Monographs · 2024Article
- Cannabis and opioid perceptions, co-use, and substitution among patients across 4 NCI-Designated Cancer Centers.Journal of the National Cancer Institute. Monographs · 2024Article
- Tobacco-cannabis co-use among cancer patients and survivors: findings from 2 US cancer centers.Journal of the National Cancer Institute. Monographs · 2024Article
- A survey of patients with cancer and oncology health-care professionals about cannabis use during treatment.Journal of the National Cancer Institute. Monographs · 2024Article
- Potential role of cannabis in ameliorating observed racialized disparities in cancer pain management.Journal of the National Cancer Institute · 2024Article
- Associations of Cancer Patients' Demographic and Clinical Characteristics With Cannabis-Related Interest and Behaviors.Journal of palliative medicine · 2024Article
- Current cannabis use and pain management among US cancer patients.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
Abstract
backgroundFor patients with cancer, marijuana may be an alternative to prescription opioid analgesics. This study analyzed self-reported marijuana and prescription opioid use among people with cancer over a 10-year time period.
methodsPopulation-based data sets from the US National Health and Nutrition Examination Survey between 2005 and 2014 were compiled for respondents aged 20 to 60 years. Respondents with cancer and respondents without cancer were propensity score-matched (1:2) by demographics to compare substance use. Outcomes included current marijuana and prescription opioid use (ie, within the past 30 days). Pearson chi-square tests and logistic regressions were performed; a 2-tailed P value < .05 was significant.
resultsThere were 19,604 respondents, and 826 people with cancer were matched to 1652 controls. Among the respondents with cancer, 40.3% used marijuana within the past year, and 8.7% used it currently. Respondents with cancer were significantly more likely to use prescription opioids (odds ratio [OR], 2.43; 95% CI, 1.68-3.57; P < .001). Cancer was not associated with current marijuana use in a multivariable conditional logistic regression but was associated with current opioid use (OR, 1.82; 95% CI, 1.17-2.82; P = .008). Among all survey respondents, the odds of marijuana use significantly increased over time (OR, 1.05; 95% CI, 1.01-1.10; P = .012), whereas the odds of opioid use did not significantly change. There were no significant differences in the longitudinal odds of marijuana or opioid use over time between respondents with a cancer diagnosis and those without one.
conclusionsThis population-based analysis revealed a considerable proportion of respondents with cancer self-reporting marijuana use (40.3%) and a significantly higher prevalence of opioid use among respondents with cancer. In the midst of an opioid epidemic, an evolving political landscape, and new developments in oncology, quantifying the prevalence of opioid and marijuana use in the US population, especially among patients with cancer, is particularly relevant. Although opioid use did not significantly change from 2005 to 2014 among all respondents, marijuana use did increase, likely reflecting increased availability and legislative changes. A cancer diagnosis did not significantly affect longitudinal opioid or marijuana use.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.